~ Buy the MYOVIEW 30ML (technetium tc-99m tetrofosmin kit) Drug Profile, 2024 PDF Report in the Report Store ~

MYOVIEW 30ML Drug Patent Profile

When do Myoview 30ml patents expire, and what generic alternatives are available?

Myoview 30ml is a drug marketed by Medi-physics and is included in one NDA. There is one patent protecting this drug.

This drug has eight patent family members in seven countries.

The generic ingredient in MYOVIEW 30ML is technetium tc-99m tetrofosmin kit. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tetrofosmin kit profile page.

DrugPatentWatch^® Generic Entry Outlook for Myoview 30ml

Myoview 30ml was eligible for patent challenges on February 9, 2000.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 10, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for MYOVIEW 30ML

International Patents:	8
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
DailyMed Link:	MYOVIEW 30ML at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MYOVIEW 30ML

Constraining patent/regulatory exclusivity:

9,549,999

NDA:

020372

Dosage:

INJECTABLE;INJECTION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for MYOVIEW 30ML

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Astellas Pharma Inc	Phase 2
GE Healthcare	Phase 4

See all MYOVIEW 30ML clinical trials

US Patents and Regulatory Information for MYOVIEW 30ML

MYOVIEW 30ML is protected by one US patents.

This potential generic entry date is based on patent 9,549,999.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medi-physics	MYOVIEW 30ML	technetium tc-99m tetrofosmin kit	INJECTABLE;INJECTION	020372-002	Jul 7, 2005		RX	Yes	Yes	9,549,999		Y

International Patents for MYOVIEW 30ML

When does loss-of-exclusivity occur for MYOVIEW 30ML?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

China

European Patent Office

Hong Kong

Japan

Spain

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MYOVIEW 30ML around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0337654	Ligands et leurs complexes avec le technétium-99m (Ligands and cationic complexes thereof with technetium-99m)
China	1024013
Denmark	171416
South Korea	0149439
United Kingdom	8808414

Supplementary Protection Certificates for MYOVIEW 30ML

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1178838	300736	Netherlands		PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119

MYOVIEW 30ML Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Myoview 30ML

Introduction to Myoview 30ML

Myoview, also known as Technetium Tc99m Tetrofosmin Injection, is a radiodiagnostic agent used for myocardial perfusion imaging (MPI) and the assessment of left ventricular function. It is indicated for patients with known or suspected coronary artery disease and heart disease, providing critical diagnostic information under rest, exercise, or pharmacologic stress conditions[2][5].

Market Size and Growth

The global market for Myoview and similar myocardial perfusion imaging agents is experiencing robust growth. This growth is driven by increasing demand for diagnostic imaging in cardiovascular diseases, advancements in nuclear medicine, and the expanding aging population who are more prone to heart conditions. The market is expected to continue its positive momentum, with anticipated expansion indicating strong growth rates in the coming years[4].

Key Market Drivers

Increasing Prevalence of Cardiovascular Diseases

The rising incidence of coronary artery disease and other heart conditions globally is a significant driver for the demand of Myoview. As the population ages and lifestyle factors contribute to higher rates of heart disease, the need for accurate and efficient diagnostic tools like Myoview increases.

Advancements in Nuclear Medicine

Technological advancements in nuclear medicine and imaging techniques have improved the efficacy and safety of radiopharmaceuticals like Myoview. These advancements enhance image quality, reduce radiation exposure, and streamline the imaging process, making Myoview a preferred choice for clinicians[5].

Efficiency in Imaging Departments

Myoview's ability to begin acquiring diagnostic information as soon as 15 minutes post-injection, its simple preparation, and high-quality images contribute to improved workflow efficiency in imaging departments. This efficiency can lead to higher patient throughput and better resource utilization, which are attractive features for healthcare providers[5].

Competitive Landscape

The market for myocardial perfusion imaging agents is competitive, with several other radiopharmaceuticals available. However, Myoview stands out due to its unique characteristics, such as its rapid imaging capability and high diagnostic accuracy. The competitive nature of the pharmaceutical industry, as seen in the development of follow-on drugs, suggests that Myoview faces competition but also benefits from the overall growth in the diagnostic imaging sector[3].

Financial Performance

Revenue Growth

The revenue generated by Myoview is expected to grow as the demand for diagnostic imaging increases. The robust growth rates anticipated in the market indicate a positive financial trajectory for Myoview. This growth is supported by the expanding use of nuclear medicine in cardiovascular diagnostics and the preference for Myoview due to its clinical benefits.

Cost-Effectiveness

Myoview's efficiency in imaging departments can lead to cost savings for healthcare providers. By reducing the time required for imaging and minimizing the need for rescans, Myoview can help lower operational costs. This cost-effectiveness is a significant factor in its financial performance and market appeal.

Challenges and Limitations

Adverse Reactions

While Myoview is generally safe, it can cause adverse reactions such as hypersensitivity, angina, and respiratory issues. These reactions, although rare, can impact patient safety and satisfaction, potentially affecting market dynamics[2][5].

Regulatory Environment

The regulatory environment for radiopharmaceuticals is stringent, and any changes in regulations or safety guidelines can impact the market. Ensuring compliance with regulatory requirements is crucial for maintaining market presence and financial stability.

Future Outlook

The future outlook for Myoview is promising, driven by the increasing demand for accurate and efficient diagnostic tools in cardiovascular medicine. As technology continues to advance and the population ages, the market for Myoview and similar agents is expected to expand.

Key Takeaways

• Growing Market Demand: Increasing prevalence of cardiovascular diseases and advancements in nuclear medicine drive the demand for Myoview.
• Efficiency and Cost-Effectiveness: Myoview's rapid imaging capability and high diagnostic accuracy contribute to its market appeal and financial performance.
• Competitive Landscape: Myoview operates in a competitive market but stands out due to its unique benefits.
• Regulatory and Safety Considerations: Adverse reactions and regulatory compliance are critical factors to consider.

Frequently Asked Questions (FAQs)

Q: What is Myoview used for? A: Myoview is used for myocardial perfusion imaging under rest, exercise, or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease[5].

Q: How soon can imaging begin with Myoview? A: Imaging can begin as soon as 15 minutes post-injection with Myoview[5].

Q: What are the common adverse reactions associated with Myoview? A: Common adverse reactions include hypersensitivity, angina, respiratory issues, and other cardiovascular and gastrointestinal symptoms[2][5].

Q: How does Myoview impact the efficiency of imaging departments? A: Myoview improves efficiency by allowing for rapid imaging, reducing the need for rescans, and providing high-quality diagnostic images[5].

Q: What are the key drivers of the market growth for Myoview? A: The key drivers include the increasing prevalence of cardiovascular diseases, advancements in nuclear medicine, and the efficiency and cost-effectiveness of Myoview[4][5].

Cited Sources

1. Cardinal Health - FDA-approved radiopharmaceuticals.
2. GE Healthcare Canada Inc. - MYOVIEWTM 30 mL [Kit for the Preparation of Technetium Tc99m Tetrofosmin Injection] Radiodiagnostic Agent.
3. PubMed - The economics of follow-on drug research and development.
4. Market Research Intellect - Global Myoview Market Size, Scope And Forecast Report.
5. GE Healthcare - Myoview™ 30mL Nuclear Imaging Agent.